Bristol Myers Squibb is a company within the Healthcare category. Bristol Myers Squibb (BMS) is a global biopharmaceutical company engaged in the discovery, development, and delivery of innovative medicines. The company focuses on serious diseases across several therapeutic areas including oncology, cardiovascular, immunology, and fibrotic diseases.
Bristol Myers Squibb was founded in 1989 (current entity) and is headquartered in Princeton, NJ.
Bristol Myers Squibb is rated Leader on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for Bristol Myers Squibb is Strong. Significant factual deltas detected.
AI models classify Bristol Myers Squibb as a Challenger. AI names competitors first.
Bristol Myers Squibb appeared in 7 of 8 sampled buyer-intent queries (88%). BMS is a dominant authority in its medical categories, but faces competition in unbranded queries from medical knowledge hubs like Mayo Clinic or WebMD.
AI models provide a highly accurate and stable view of BMS as a top-tier pharmaceutical leader. They reliably detail its history, major acquisitions, and top-selling drugs, though they may struggle with the most recent tactical shifts in R&D pipeline prioritization announced in late 2024. Key gap: AI may lag in reflecting the specific impact of the 2024 'Strategic Productivity Initiative' (restructuring) on the current workforce and R&D pipeline priorities.
Of 6 key facts verified about Bristol Myers Squibb, 5 are well-documented (likely accurate across AI models), 1 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.
The specific current status of early-stage pipeline assets (Phase I/II) is the most likely area for hallucination or outdated information.
Buyers turn to Bristol Myers Squibb for Internal Drug Discovery: Internal R&D departments at large healthcare organizations attempting to synthesize similar compounds or therapies., CRO Partnerships: Contract Research Organizations (CROs) hired to manage clinical trials and development that a company might otherwise partner with BMS for., among 2 documented problem areas.
Buyers evaluating Bristol Myers Squibb typically ask AI models about "top oncology pharmaceutical companies", "who makes opdivo", "immunotherapy manufacturers", and 4 similar queries.
Bristol Myers Squibb's main competitors are AstraZeneca, Novartis, Pfizer. According to AI models, these are the brands most frequently named alongside Bristol Myers Squibb in buyer-intent queries.
Bristol Myers Squibb's core products are Opdivo, Eliquis, Orencia, Revlimid, Pomalyst, Abecma, Camzyos.
Bristol Myers Squibb uses Healthcare Reimbursement / Enterprise/Custom.
Bristol Myers Squibb serves Global healthcare providers, hospitals, and patients in oncology, immunology, and cardiovascular care..
Bristol Myers Squibb BMS maintains one of the world's most advanced oncology and hematology portfolios, specifically leading in immunotherapy and cell therapy.
Brand Authority Index (BAI) tier: Leader (exact score locked for unclaimed brands)
Archetype: Challenger
https://optimly.ai/brand/bristol-myers-squibb
Last analyzed: April 10, 2026
Founded: 1887 (Bristol-Myers) / 1858 (Squibb) / 1989 (Merger)
Headquarters: Princeton, New Jersey, USA